AstraZeneca Announces Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase III Trials
December 1, 2023: AstraZeneca announced that it has decided to discontinue the STABILIZE-CKD trial and the DIALIZE-Outcomes Phase III trial that evaluate zirconium cyclosilicate sodium hydrate (product name: Lokelma) due to delays in patient enrollment and low event rates. The two studies were designed to evaluate the effects of the drug on the cardiac and renal systems.
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides valuable information on Cardiovascular medicine to medical professionals worldwide.
We bring you the latest findings and trends in all areas of cardiovascular medicine. Please register and subscribe for unlimited access to quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.